Has the era of AI's iPhone begun? Altman targets AI hardware with a single image to understand his billion dollar investment empire
123458086
发表于 2024-4-8 13:38:36
1332
0
0
On April 6th local time, according to technology media The Information, Sam Altman, CEO of OpenAI, and former Apple design director Johnny Avi, a startup founded by OpenAI, announced new financing news. It is reported that the two have teamed up to develop an AI powered personal device and are currently seeking $1 billion in financing.
CandyLake.com is an information publishing platform and only provides information storage space services.
Disclaimer: The views expressed in this article are those of the author only, this article does not represent the position of CandyLake.com, and does not constitute advice, please treat with caution.
Disclaimer: The views expressed in this article are those of the author only, this article does not represent the position of CandyLake.com, and does not constitute advice, please treat with caution.
转播
You may like
- Elon Musk is in the game! Understanding the highlights of Tesla Robotaxi Day in one article
- How will 'Trump 2.0' affect the prospect of Fed interest rate cuts? One article comprehension
- Which sectors and individual stocks can receive sustained boost from Trump's victory in leading the US stock market? One article comprehension
- Eli Lilly's new Alzheimer's disease drug Donanemab has been approved for pricing in Japan
- One picture to understand | JD's third quarter report is about to be released! What are the highlights?
- How Trump 2.0 will govern depends entirely on how the US stock market performs? One article comprehension
- Eli Lilly's Alzheimer's disease therapy, Minolta (Donaimab Injection), has been approved in China
- Eli Lilly's Alzheimer's disease treatment with donentinumab injection approved
- Eli Lilly's Alzheimer's disease therapy, Minolta (Donaimab Injection), has been approved in China
- Eli Lilly's new Alzheimer's disease drug launched: annual drug cost exceeds $30000, Pfizer Roche is expanding its strategy
